Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-319 in active/refractory SLE
NCT06400537Phase 1Recruiting
- Start
- Jul 2024
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of A-319 in systemic lupus erythematosus (SLE) (2 arms). Primary endpoint: Safety and tolerability at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
A-319
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06400537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400537.